Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 4/20 | 0.39 |
| ▸ | CDK2 | P24941 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4834961 | 0.93 | CDK4 (0.35) | KDM1AALDH1A1HPGDCDK4CDK2 | |
| SCHEMBL5260102 | 0.89 | MAPK1 (0.40) | KDM1AALDH1A1HPGDCDK4CDK2 | |
| SCHEMBL4835015 | 0.85 | ACHE (0.44) | ACHE | |
| SCHEMBL5257529 | 0.85 | MEN1 (0.42) | KDM1AALDH1A1CDK4CDK2KMT2A | |
| SCHEMBL4842028 | 0.83 | MAPK1 (0.46) | KMT2AKDM4EMAPK1TDP1ACHE | |
| SCHEMBL5256838 | 0.83 | KMT2A (0.39) | KDM1ACDK4CDK2KMT2AKDM4E | |
| SCHEMBL5255347 | 0.83 | ALDH1A1 (0.51) | ALDH1A1KMT2AMAPK1MEN1 | |
| Trifluoroacetic Acid SCHEMBL4840566 | 0.82 | ALDH1A1 (0.39) | KDM1AALDH1A1CDK4CDK2KMT2A | |
| SCHEMBL4837757 | 0.81 | ALDH1A1 (0.37) | KDM1AALDH1A1HPGDCDK4CDK2 | |
| Trifluoroacetic Acid SCHEMBL4842600 | 0.80 | CYP2D6 (0.40) | ALDH1A1CDK4CDK2KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539759-B1 | NOVEL IMIDAZOPYRIDINES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | claimed |
| US-20050261333-A1 | Use of and some novel imidazopyridines | ASTRAZENECA A B (SE) | 2005-11-24 | — | — | US | claimed |
| US-7410966-B2 | Use of and some novel imidazopyridines | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | disclosed |
| EP-1539759-B1 | NOVEL IMIDAZOPYRIDINES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | disclosed |
| US-20050261333-A1 | Use of and some novel imidazopyridines | ASTRAZENECA A B (SE) | 2005-11-24 | — | — | US | disclosed |
| EP-1539759-A1 | USE OF AND SOME NOVEL IMIDAZOPYRIDINES | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004016611-A1 | USE OF AND SOME NOVEL IMIDAZOPYRIDINES | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261333-A1 | Use of and some novel imidazopyridines | ITK, CSNK1A1, RPS6KA1 | KDM1A 2854/4885ALDH1A1 1489/4885HPGD 1597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.